[HTML][HTML] Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV
MT Bennett, KW Johns, GP Bondy - Lipids in Health and Disease, 2007 - Springer
MT Bennett, KW Johns, GP Bondy
Lipids in Health and Disease, 2007•SpringerTo determine the efficacy and safety of adding ezetimibe to maximally tolerated lipid
lowering therapy in patients with HIV dyslipidemia. Retrospective analysis of lipid
parameters was conducted for 33 patients with HIV who had been prescribed ezetimibe 10
mg per day. Mean total cholesterol was reduced 21%(p< 0.001). Mean LDL was reduced
35%(p< 0.001). Mean HDL increased 8%(p= 0.038). Mean triglyceride was reduced 34%(p=
0.006). Mean Apolipoprotein B100 was reduced 33%(p= 0.043). No adverse events …
lowering therapy in patients with HIV dyslipidemia. Retrospective analysis of lipid
parameters was conducted for 33 patients with HIV who had been prescribed ezetimibe 10
mg per day. Mean total cholesterol was reduced 21%(p< 0.001). Mean LDL was reduced
35%(p< 0.001). Mean HDL increased 8%(p= 0.038). Mean triglyceride was reduced 34%(p=
0.006). Mean Apolipoprotein B100 was reduced 33%(p= 0.043). No adverse events …
Abstract
To determine the efficacy and safety of adding ezetimibe to maximally tolerated lipid lowering therapy in patients with HIV dyslipidemia.
Retrospective analysis of lipid parameters was conducted for 33 patients with HIV who had been prescribed ezetimibe 10 mg per day.
Mean total cholesterol was reduced 21% (p < 0.001). Mean LDL was reduced 35% (p < 0.001). Mean HDL increased 8% (p = 0.038). Mean triglyceride was reduced 34% (p = 0.006). Mean Apolipoprotein B100 was reduced 33% (p = 0.043). No adverse events occurred.
Ezetimibe appears safe and effective in patients with HIV when added to maximally tolerated doses of lipid lowering therapy.
Springer
